Yahoo Finance • yesterday
[US Food and Drug Administration (FDA)] Aurinia Pharmaceuticals (NASDAQ:AUPH [https://seekingalpha.com/symbol/AUPH]) traded ~7% higher in the premarket on Tuesday after the company responded to a comment made by a top FDA regulator regard... Full story
Yahoo Finance • 4 days ago
If you own Roche Holding stock or are weighing whether now is the right time to step in, you are not alone. The recent price action has certainly caught the eye of investors. Roche’s shares closed at 253.5, down 4.4% over the past week and... Full story
Yahoo Finance • 9 days ago
Check out the companies making headlines in midday trading : Better Home & Finance Holding — The mortgage lender briefly soared as much as 176% Monday after hedge fund manager Eric Jackson in a social media post on X called Better Home "th... Full story
Yahoo Finance • 9 days ago
Check out the companies making headlines before the opening bell : Metsera , Pfizer — The weight-loss drugmaker soared 60% after an announcement it would be bought by Pfizer for $4.9 billion in cash. The deal is expected to close in the fo... Full story
Yahoo Finance • 20 days ago
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers Vinay Prasad, a top US FDA official who left [https://seekingalpha.com/news/4474009-fda-vaccines-head-chief-medical-officer-vinay-prasad-departs-agency]the agency in la... Full story
Yahoo Finance • 23 days ago
Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value met... Full story
Yahoo Finance • 27 days ago
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trading at $... Full story
Yahoo Finance • 28 days ago
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Mid-cap stocks rebounded in the second quarter,... Full story
Yahoo Finance • last month
SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22,... Full story
Yahoo Finance • last month
Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • last month
Elanco Animal Health (NYSE:ELAN [https://seekingalpha.com/symbol/ELAN]) will replace Sarepta Therapeutics (NASDAQ:SRPT [https://seekingalpha.com/symbol/SRPT]) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp (... Full story
Yahoo Finance • last month
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P... Full story
Yahoo Finance • last month
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story
Yahoo Finance • last month
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22,2... Full story
Yahoo Finance • last month
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle... Full story
Yahoo Finance • last month
Investing.com - Mizuho maintained its Neutral rating and $19.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) following the company’s second-quarter 2025 earnings report and debt refinancing. The stock, currently trading at $20.22,... Full story
Yahoo Finance • last month
NEW YORK, Aug. 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“... Full story
Yahoo Finance • last month
SAN FRANCISCO, Aug. 23, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT), triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS.... Full story
Yahoo Finance • last month
NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives f... Full story
Yahoo Finance • last month
NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story